Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment.
Elliot
V
V
Marin
D
D
Horncastle
D
D
Elderfield
K
K
Howard
J
J
Apperley
J F
JF
Lampert
I A
IA
Naresh
K N
KN
D018952:Antigens, CD34 / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001707:Biopsy, Needle; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D002452:Cell Count; D006412:Hematopoietic Stem Cells / Q000378:metabolism / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate